JNJ - Johnson & Johnson
| Previous close | 138.61 |
| Open | 138.61 |
| Bid | 138.42 x 2200 |
| Ask | 139.38 x 800 |
| Day's range | 137.68 - 138.96 |
| 52-week range | 118.62 - 148.99 |
| Volume | 4,366,393 |
| Avg. volume | 6,225,661 |
| Market cap | 367.513B |
| Beta (3Y monthly) | 0.68 |
| PE ratio (TTM) | 25.65 |
| EPS (TTM) | 5.40 |
| Earnings date | 16 Jul 2019 |
| Forward dividend & yield | 3.80 (2.69%) |
| Ex-dividend date | 2019-05-24 |
| 1y target est | 148.12 |
- Zacks•18 hours ago
Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
- Zacks•yesterday
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
- Zacks•yesterday
AbbVie's Brain Cancer Candidate Fails in Phase III Study
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
- Motley Fool•3 days ago
6 Things Johnson & Johnson Wants You to Know About Its Pharmaceuticals
Here's what management wants investors to know about the future of the company's pharmaceutical segment.
- Zacks•4 days ago
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
- Motley Fool•5 days ago
Did Geron's Big Announcement Just Go Unnoticed?
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
- Barrons.com•5 days ago
Johnson & Johnson Is a Defensive Stock. Now There’s Hope for Growth.
Sales at Johnson & Johnson ‘s pharmaceutical business are poised to surge to $50 billion by 2023—a leap of more than 20%.
- Zacks•5 days ago
Why Is Johnson & Johnson (JNJ) Down 1.2% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•12 days ago
Perrigo (PRGO) Beats on Q1 Earnings and Sales, Stock Up
Perrigo (PRGO) reports encouraging first-quarter 2019 results. The Rx segment recovers during the quarter on strong new product sales.
Associated Press•13 days agoTV pitches for prescription drugs will have to include price
WASHINGTON (AP) — TV pitches for prescription drugs will soon include the price, giving consumers more information upfront as they make medication choices at a time when new drugs can carry anxiety-inducing prices.
- Zacks•13 days ago
Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates
Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.
- Bloomberg•14 days ago
J&J Pays About $1 Billion to Resolve Pinnacle-Hip Suits
With the agreement, J&J has now resolved more than 95 percent of the 6,000 cases in which surgeons extracted the Pinnacle implants because of defects that left patients unable to walk and in pain, according to two people familiar with the settlements. Rather than set up a global settlement program, attorneys for J&J and its DePuy unit, maker of the Pinnacle hip replacements, cut separate deals with plaintiffs’ lawyers to resolve their clients’ cases, the people said. Mindy Tinsley, a J&J spokeswoman, said Tuesday in a statement that settlement negotiations for the Pinnacle cases are continuing and that the world’s largest maker of health care products had set aside funds for the litigation.
- Zacks•15 days ago
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
Bloomberg•15 days agoBoeing’s 737 Max Defense Is a Textbook Mess
In the future, we can expect Boeing Co.’s treatment of its two 737 Max crashes to join the syllabus — as an example of what not to do. Engineers at the planemaker discovered problems with the aircraft’s angle-of-attack sensors within months of the model’s first delivery, but didn’t share its findings with airlines, regulators or even senior management until much later, the company said Sunday. When Johnson & Johnson found someone was lacing the pain-relief medicine with cyanide, it removed the product from shelves and followed a policy of maximum transparency to reassure customers.
- Motley Fool•16 days ago
Where Will Johnson & Johnson Be in 10 Years?
Predicting the future is never easy, but here's what might be in store for the healthcare giant.
- Zacks•18 days ago
Lowest Unemployment Rate in 50 Years: What To Buy
263,000 jobs were added to the market in April, and the unemployment rate fell to 3.6%, the lowest jobless claim since December of 1969.
- Zacks•18 days ago
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
- Motley Fool•18 days ago
Pacira BioSciences Rocks in Q1 With Strong Momentum for Pain Drug Exparel
The small drugmaker posted record sales for its flagship drug in the first quarter.
- Motley Fool•19 days ago
2 Dividend Stocks to Supplement Your Social Security Income
These outstanding businesses can put more money in your pocket every year.
- Zacks•19 days ago
Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses
Glaxo (GSK) beats earnings and sales estimates for the first quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
- Zacks•19 days ago
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
- Simply Wall St.•20 days ago
How Much Did Johnson & Johnson's (NYSE:JNJ) CEO Pocket Last Year?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Alex Gorsky became the CEO of Johnson & Johnson (NYSE:JNJ) in 2012. This analysis aims fir...
- Zacks•21 days ago
Merck (MRK) Beats on Q1 Earnings & Sales as Keytruda Shines
Merck (MRK) beats estimates for earnings as well as sales in first-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
